In rheumatic heart disease–associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y
Annals of Internal Medicine · 2023
DOI: 10.7326/j22-0102 ↗Kurz gefasst
Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Ellis W Lader. Beteiligte Einrichtung: WMCHealth Heart and Vascular Institute, Kingston, New York, United States (E.W.L.). Hauptthemen laut MEDLINE: Rheumatic Heart Disease, Atrial Fibrillation, Stroke.
Abstract (Originalsprache)
SOURCE CITATION: Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med. 2022;387:978-88. 36036525.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- WMCHealth Heart and Vascular Institute, Kingston, New York, United States (E.W.L.).
Zitieren
APA
Lader, E. W. (2023). In rheumatic heart disease–associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y. Annals of Internal Medicine. https://doi.org/10.7326/j22-0102
Vancouver
Lader EW. In rheumatic heart disease–associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y. Annals of Internal Medicine. 2023. doi:10.7326/j22-0102
BibTeX
@article{Lader2023,
author = {Lader, Ellis W},
title = {In rheumatic heart disease–associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y},
journal = {Annals of Internal Medicine},
year = {2023},
doi = {10.7326/j22-0102}
}
EUVIMED